Scott Turner

Company: Pliant Therapeutics Inc.

Job title: Senior Vice President , Research


The Road to Success: Selectively Targeting TGF-β for Antifibrotic Drug Development & Harnessing the Translational Insights for Immuno-Oncology 9:00 am

Highlighting the discovery and development of PLN-74809, a dual selective integrin inhibitor for pulmonary fibrosis Uncovering Pliant’s translational approach and successful Phase 2 results in IPF Reprogramming the tumor microenvironment with selective inhibition of TGF-β Discussing blocking integrin activation of TGF-β to increase checkpoint inhibitor efficacy and targeting immune and stromal activation of TGF-βRead more

day: Day One

Discussion Panel: Forecasting the Future Developments in Targeting TGF-β for Immuno-Oncology: Where May the Next 3-5 Years Take Us? 12:00 pm

Read more

day: Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.